Asset
IOPOFOSINE I-131
Cellectar Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03478462 | phase1 | active_not_recruiting | 2019-04-30 | 2026-08-25 | Cellectar Biosciences, Inc. | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas |
| NCT05610891 | phase1 | active_not_recruiting | 2023-10-01 | 2026-05-01 | Cellectar Biosciences, Inc. | Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG |
FDA applications (0)
This company has no applications containing this asset.